We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
-5.96%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$4.19B
AUM Growth
-$667M
Cap. Flow
-$151M
Cap. Flow %
-3.6%
Top 10 Hldgs %
47.69%
Holding
131
New
13
Increased
16
Reduced
22
Closed
21

Top Buys

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$101M
2
SION
Sionna Therapeutics
SION
+$60.5M
3
AXSM icon
Axsome Therapeutics
AXSM
+$44.1M
4
APLS
Apellis Pharmaceuticals
APLS
+$39.6M
5
UNH icon
UnitedHealth
UNH
+$35.9M

Top Sells

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$117M
2
MRK icon
Merck
MRK
+$82.6M
3
BIIB icon
Biogen
BIIB
+$77.9M
4
ISRG icon
Intuitive Surgical
ISRG
+$61.2M
5
UHS icon
Universal Health Services
UHS
+$48.3M

Sector Composition

Rank Sector Weight
1 Healthcare 98.96%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SIBN icon
26
SI-BONE Inc
SIBN
$809M
$48.3M 1.15%
3,442,853
– –
AXSM icon
27
Axsome Therapeutics
AXSM
$11.7B
$45.1M 1.08%
+386,700
New +$44.1M
CMPX icon
28
Compass Therapeutics
CMPX
$355M
$42.5M 1.01%
22,362,850
– –
SWTX
29
DELISTED
SpringWorks Therapeutics
SWTX
$41.9M 1%
950,200
-304,831
-24% -$14M
NPCE icon
30
Neuropace
NPCE
$483M
$41.9M 1%
3,406,335
– –
SION
31
Sionna Therapeutics
SION
$2.04B
$38.8M 0.92%
+3,704,959
New +$60.5M
UPB
32
Upstream Bio Inc
UPB
$342M
$34.8M 0.83%
5,693,589
– –
XTNT icon
33
Xtant Medical Holdings
XTNT
$59.1M
$34.4M 0.82%
73,114,592
– –
TARS icon
34
Tarsus Pharmaceuticals
TARS
$2.53B
$33.6M 0.8%
+653,743
New +$32.3M
CRNX icon
35
Crinetics Pharmaceuticals
CRNX
$8.88B
$33.5M 0.8%
999,000
– –
XENE icon
36
Xenon Pharmaceuticals
XENE
$6.17B
$31.8M 0.76%
947,877
– –
APLS
37
DELISTED
Apellis Pharmaceuticals
APLS
$31.3M 0.75%
+1,432,300
New +$39.6M
MBX
38
MBX Biosciences
MBX
$2.97B
$29.5M 0.7%
4,002,887
+190,672
+5% +$2.02M
EXAS
39
DELISTED
Exact Sciences
EXAS
$29.4M 0.7%
679,816
– –
GILD icon
40
Gilead Sciences
GILD
$166B
$22.1M 0.53%
197,500
-48,100
-20% -$4.96M
CRVS icon
41
Corvus Pharmaceuticals
CRVS
$1.1B
$22.1M 0.53%
6,943,654
– –
TERN
42
DELISTED
Terns Pharmaceuticals
TERN
$20.9M 0.5%
7,562,971
– –
JANX icon
43
Janux Therapeutics
JANX
$900M
$20.5M 0.49%
758,566
– –
RYTM icon
44
Rhythm Pharmaceuticals
RYTM
$7.35B
$20.1M 0.48%
380,000
-20,000
-5% -$1.11M
THRD
45
DELISTED
Third Harmonic Bio
THRD
$20.1M 0.48%
5,779,071
– –
FOLD
46
DELISTED
Amicus Therapeutics
FOLD
$18.6M 0.44%
2,285,400
– –
VSTM icon
47
Verastem
VSTM
$520M
$17.3M 0.41%
2,862,448
– –
TYRA icon
48
Tyra Biosciences
TYRA
$1.81B
$16.3M 0.39%
1,752,831
+282,745
+19% +$3.66M
RAPT
49
DELISTED
RAPT Therapeutics
RAPT
$16M 0.38%
1,641,908
– –
SCPH
50
DELISTED
scPharmaceuticals
SCPH
$15.9M 0.38%
6,059,528
– –
1
2
3 4 5

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
SGM
Skye Global Management West Palm Beach, Florida $5B AUM 11.9% 1-Year Est. Return

OrbiMed's Q1 2025 Portfolio in Review

As of Q1 2025, OrbiMed held 131 positions worth $4.19B, down 14% from $4.86B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

OrbiMed withdrew a net $151M in Q1 2025, closing 21 positions and reducing 22 holdings. Its most notable exit was Sarepta Therapeutics, an estimated $117M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 98% a quarter earlier.

Against the trend, OrbiMed opened a new position in Pfizer worth $97.6M.

  • OrbiMed's largest Q1 2025 buy was Pfizer: 3,850,200 shares worth $97.6M.
  • OrbiMed added most to UnitedHealth in Q1 2025, an estimated $35.9M increase.
  • OrbiMed's biggest Q1 2025 reduction was Intuitive Surgical, cutting an estimated $61.2M.
  • OrbiMed fully exited Sarepta Therapeutics in Q1 2025, selling an estimated $117M.
  • OrbiMed's ten largest holdings make up 48% of its $4.19B portfolio in Q1 2025.
  • OrbiMed opened 13 new positions and closed 21 in Q1 2025.
  • OrbiMed's portfolio value fell 14% quarter-over-quarter to $4.19B.

Based on OrbiMed's 13F filing for Q1 2025, filed 15 May 2025.